GB261 combines the well-established anti-CD20 cancer drug rituximab with an anti-CD3 antibody arm ... Using CAAD and epitope binning, multiple VHHs binding to different predicted epitopes on ...

Compared with small molecules and conventionally selected antibodies, epitope-selective antibodies exhibit precise target selectivity that confers enhanced safety and pharmacodynamic properties.

ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IV BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal ...

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the ...

Title: Switching to Ublituximab from Prior anti-CD20 Monoclonal Antibody Therapy: A Case Report Series The article describes a retrospective case series of seven individuals with multiple ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.